Advaxis, Inc. (NASDAQ:ADXS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research firms also recently issued reports on ADXS. ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a research report on Monday, June 12th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the stock a “buy” rating in a research report on Wednesday, June 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $22.00.

Advaxis (NASDAQ ADXS) traded up 2.92% during mid-day trading on Friday, reaching $7.41. The company had a trading volume of 472,768 shares. Advaxis has a 12-month low of $5.70 and a 12-month high of $12.66. The stock has a 50-day moving average of $6.50 and a 200 day moving average of $7.54. The company’s market capitalization is $299.82 million.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/advaxis-inc-adxs-upgraded-to-buy-by-bidaskclub.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stevens Capital Management LP purchased a new position in shares of Advaxis in the first quarter valued at $105,000. Voya Investment Management LLC grew its position in shares of Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares in the last quarter. Cutler Capital Management LLC purchased a new position in shares of Advaxis in the second quarter valued at $130,000. American International Group Inc. grew its position in shares of Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 1,459 shares in the last quarter. Finally, Northern Capital Management LLC grew its position in shares of Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,650 shares in the last quarter. Institutional investors own 48.78% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.